Phase 3 Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b in Combination With Ribavirin Compared With Peginterferon Alfa-2a in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 1. ACHIEVE-1.
Phase of Trial: Phase III
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Albinterferon alfa 2B; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ACHIEVE-1
- Sponsors Human Genome Sciences
- 29 Jun 2012 Companies added in the association field as reported by EudraCT.
- 29 Aug 2011 Additional trial identifiers ACTRN12607000093482, 081724 identified as reported by Australian New Zealand Clinical Trials Registry.
- 29 Aug 2011 New source identified (Australian New Zealand Clinical Trials Registry).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History